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Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival. Therefore, individual
assessment of a tumor’s aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large
number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens.
However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies
is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies.
1. Introduction
Prostate cancer is the most common cancer in Western men.
Although prostate cancer follows an aggressive course in a
significant number of men, most tumors do not cause signif-
icant clinical symptoms. Therefore individual assessment of
a tumor’s aggressive potential is crucial for clinical decision-
making in men with prostate cancer.
In general, prostate cancer is diagnosed on needle-bio-
psies prompted by elevated serum prostate specific antigen
(PSA) levels, suspicious digital rectal examination or trans-
rectal ultrasonography findings, and/or clinical symptoms
of urinary tract obstruction. In addition to elevated PSA
levels and clinicoradiological signs of either local extension
or metastasis, detailed histopathological characterization of
prostate cancer at needle-biopsies predicts clinical tumor
behavior and sustains therapeutic decision-making. In daily
practice, the pathology report of prostate cancer includes
the grade of differentiation according to the modified Glea-
son grading system, the number of biopsies infiltrated by
prostate cancer, and a quantitative assessment of the tumor
volume per biopsy in either length in mm or percentage
of tumor [1, 2]. Implementation of novel histopathological
and molecular markers is required for several reasons. While
only half of the patients has a potentially life-threatening
prostate cancer (Gleason score ≥ 7), 55–90% of patients
with low-risk disease still undergo radical prostatectomy [3].
Active surveillance has become a widely used alternative
for treatment after prostate cancer diagnosis. However, up
to 33% of patients on active surveillance need therapeutic
intervention after a median follow-up of 1.2–3.5 years [4–8].
Therefore, better stratification of prostate cancer patientswith
respect to clinical decision-making is necessary, especially in
the predominant group of low- to intermediate-risk prostate
cancers.
Another reason to implement novel markers in prostate
cancer diagnosis and clinical decision-making is the consid-
erable interobserver variability in Gleason grading among
pathologists. This interobserver variability is particularly of
significance in the large group of low- to intermediate-risk
prostate cancer, as it can influence therapeutic approaches
[8–10]. Contemporary modified Gleason grading in needle-
biopsies demands adding the most common and highest
Gleason grade to the final Gleason score, regardless of the
amount of “highest” Gleason grade. In practice, when only
a few atypical glands considered Gleason grade 4 are present
together with a large volume of Gleason grade 3, the Gleason
score is 7 and excludes patients from active surveillance in
our institute. As considerable interobserver variability exists
between the distinction of Gleason grades 3 and 4, important
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treatment decisions depend too much on individual pathol-
ogist’s opinions. Thus, it is important to improve the repro-
ducibility of Gleason grading by more objective parameters.
In particular, molecular markers reflecting tumor biology
could act as novel threshold in active surveillance or watchful
waiting.
Finally, spatial heterogeneity of prostate cancer might
lead to under- or, rarely, overestimation of prostate cancer
aggressive potential on diagnostic needle-biopsies. In general,
prostate biopsies only sample 0.05% to 0.5% of the total
prostate volume, which might result in undersampling of
the most significant area of prostate cancer tissue. In addi-
tion to improved image-guided needle-biopsy procedures,
implementation of novel molecular markers might predict
the presence of unsampled significant areas in case molecular
aberrations precede pathologically discernible patterns.
Last decade,much effort has been put in the identification
of novel histopathological and molecular markers to further
improve prediction of tumor behavior in prostate cancer
patients. The vast majority of research has focused on corre-
lation of novel markers with static clinicopathologic param-
eters at radical prostatectomy such as Gleason score, pT-
stage and surgical margin status, or biochemical recurrence
after operation. However, in order to affect clinical decision-
making, validation of respective markers in pretreatment
diagnostic needle-biopsies is essential. Here, we discuss
established and promising histopathological and molecular
tissue markers in diagnostic needle-biopsies.
2. Pathologic Markers
2.1. Gleason Grading. The contemporary system for grading
prostate cancer was developed by Gleason in the 1960s [11].
The Gleason grading system is solely based on the tumor’s
architecture. The Gleason score equals the sum of the two
most common Gleason grades in radical prostatectomy,
and the sum of the most common and highest Gleason
grades in needle-biopsies. Up to date, the Gleason score is a
strong predictor for disease progression, and one of the most
important parameters in therapeutic decision-making.
In 2005, the Gleason grading system was modified at the
International Society of Urological Pathology (ISUP) confer-
ence [1]. As a result, several tumor growth patterns classically
considered as Gleason grade 3 were redefined as Gleason
grade 4 [1]. Shortly after, small cribriform and glomeruloid
glands have been reconsidered Gleason grade 4 as well [12–
14]. As a result of this stage migration, Gleason score 7
has become the most common assigned score on prostatic
needle-biopsies [15–17]. For instance, Helpap and Egevad
showed in 368 needle-biopsy cases a significant change in
distribution of modified Gleason score: Gleason score 2–4
decreased from 2.7 to 0%, Gleason score 5 decreased from 2.7
to 0%,Gleason score 6 decreased from48 to 22%, butGleason
score 7 increased from 26 to 68% [16]. Generally, modified
Gleason grading has improved the predictive value of grading
prostate cancer.
2.1.1. Modified Gleason Grading: Up- and Downgrading.
The overall concordance of Gleason score between prostate
needle-biopsies and radical prostatectomies has improved
from58% in classicGleason score to 72% inmodifiedGleason
score [16]. Uemura et al. found a decrease in downgrading
Gleason score in needle-biopsies in comparison to radical
prostatectomy (15% versus 20%), although overall Gleason
score concordance rates did not change significantly [18].
To date, the overall upgrading rate at radical prostatectomy
using the modified Gleason score ranges between 26 and
50% [19–22]. For instance, a large study containing 7643
radical prostatectomies with corresponding needle-biopsies
demonstrated that 36% of cases (1841/5071) were upgraded
from a needle-biopsy Gleason scores 5-6 to a higher grade at
radical prostatectomy [19]. In the same study 72% (1143/1577)
had matching Gleason score 7 on biopsy and radical prosta-
tectomy, and Gleason score 8 on biopsy showed a similar
distribution for radical prostatectomy Gleason score 4 + 3 =
7, 8, and 9-10 [19]. In men with Gleason score 9-10 on needle-
biopsy, 58% (69/119) had a similar Gleason score on radical
prostatectomy [19]. Proposed predictors for upgrading are
age, high preoperative PSA, larger tumor percentage per core,
number of positive cores, presence of perineural invasion,
absence of inflammation, and high prostate volume [19, 21].
On the other hand, predictors for downgrading from any
biopsy Gleason score to a lower Gleason score on radical
prostatectomy were low preoperative PSA, lower tumor
percentage per core, and larger prostate volume on radical
prostatectomy [19, 21]. Although these predictors for up- and
downgrading all showed strong statistical significance, the
effect on survival was still small. If in one biopsy session,
multiple biopsies show differing Gleason scores, for instance,
Gleason scores 4 + 3 in one biopsy and 3 + 3 in another
biopsy, also referred to as presence of ComboGS, patients
have lower odds of upgrading at time of radical prostatectomy
and decreased risk of prostate cancer specific mortality [23,
24].
2.1.2. Modified Gleason Grading: Correlation with Pathologic
Features at Radical Prostatectomy. The relationship between
Gleason score on needle-biopsy and pathological stage on
radical prostatectomy has improved since the implementa-
tion of the modified Gleason score [15, 25]. For instance,
4315/5205 men (83%) with Gleason score 6 on biopsy had
organ-confined disease (pT2) at radical prostatectomy, while
increasing Gleason score on biopsy was strongly associated
with extraprostatic extension (pT3a) and seminal vesicle
invasion (pT3b) [25]. Although high pathologic stage is
related to positive surgical margins at radical prostatectomy
and biochemical recurrence, it should be mentioned that it is
not associated with a uniformly poor prognosis [26–28].
2.1.3. Modified Gleason Grading: Predicting Patient Outcome.
Billis et al. studied the impact of needle-biopsy Gleason
score modification on biochemical recurrence free survival.
Here, the modified Gleason score was a better predictor for
biochemical recurrence than classic Gleason score [15]. Sub-
sequently, the predictive value of the modified Gleason score
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has been validated in other large cohorts [18, 25]. Uemura et
al. showed that theGleason scorewas strongly associatedwith
biochemical recurrence, only when the modified Gleason
score was applied [18]. Furthermore, in a large study (𝑛 =
7850) from the Johns Hopkins Hospital, Pierorazio et al.
correlated biopsyGleason scorewith biochemical recurrence.
Here, 95% of the patients with needle-biopsy Gleason score
6 had no biochemical recurrence after 5 years of follow-up
[25]. In men with Gleason score 3 + 4 = 7 and Gleason score
4 + 3 = 7 on needle-biopsy the 5 year biochemical recurrence
free survival rates were 83% and 65%, respectively. Men with
Gleason score 4 + 4 = 8 or 9-10 had the lowest 5 year biochem-
ical recurrence free survival rates, 63% and 35% respectively.
Tollefson et al. indicated that distant metastasis and disease-
specific death are best estimated by a combination of Gleason
score, perineural invasion, and Ki-67 expression [29].
Altogether, modified Gleason grading has generally
improved the concordance between biopsy and radical
prostatectomy Gleason score, associates better with patho-
logic parameters at radical prostatectomy, and is more pre-
dictive for biochemical recurrence as well as metastasis and
disease-specific death.
2.2. Tumor Quantification. Currently, the number of positive
core biopsies should routinely be mentioned in pathology
reports. Additional measures of prostate cancer volume
in needle-biopsies better predict disease outcome. Various
parameters have been proposed as measure of tumor extent,
for example, tumor percentage in single biopsies, tumor
length in single biopsies (mm), and number of negative biop-
sies. These quantitative assignments are required for most
clinical nomograms. For instance, the Steyerberg nomogram
incorporates number of positive biopsies, total cancer length
(mm), and total “normal” tissue length (mm) to predict
indolent disease on radical prostatectomy [30]. In addition,
most active surveillance protocols are delimitated by the
number of positive biopsies and/or ameasure of tumor extent
per biopsy [31, 32].
One well-studied example of tumor extent is the per-
centage of cancer in single biopsies, and many studies have
confirmed its prognostic value in biopsies followed by radical
prostatectomy [19, 25, 33–37], by dose-escalated external
beam radiotherapy [38], or by a combination with hormonal
treatment [39].The location of positive biopsies can addition-
ally be of therapeutic value, for instance for consideration
of nerve-sparing surgery. The majority of these studies
agree on the predictive value of tumor extent for endpoints
such as biochemical recurrence [19, 25, 35–38, 40],metastasis
[36–38], and disease-specific death [36, 38]. However, despite
its statistical significance, the effect of tumor percentage in
biopsies on survival is mostly small. Furthermore, all of
the above mentioned publications used different methods
to determine the percentage of cancer and different cutoff
values. For instance, Vance et al. divided the percentage of
cancer in single biopsies into four quartiles (<2.5%, <10%,
<25%, and ≥25%) [38], while Nelson et al. categorized it in
to 0–10%, 11–59%, and 60–100% [36].
Another frequently assessedmeasure on prostate biopsies
is the percentage of positive biopsy cores, defined as the
total number of positive cores divided by the total number
of biopsy cores obtained. Studies evaluating its prognostic
value have validated the independent predictive value for
biochemical recurrence free survival [35, 39, 41, 42]. In 2011
Huang et al. analyzed needle-biopsies of 1056 patients treated
with external beam radiotherapy and/or hormonal therapy
[43]. Using a cutoff value of >50% positive biopsy cores
they found that percentage of positive biopsy cores is a
powerful and independent predictor for distant metastasis
free and overall survival [43]. However, when the percentage
of positive biopsy cores was adjusted for percentage of
cancer in needle-biopsies in another study, it did not provide
any additional superior risk stratification for biochemical
recurrence, distant metastasis, or disease-specific death [38].
While measuring tumor extent is generally straight-
forward, minor controversies exist for instance for quanti-
fying discontinuous prostate cancer foci in single biopsies.
One could regard separate foci as being part of the same
tumor and measure the distance between the outermost foci
including intervening normal prostate tissue, or onlymeasure
malignant areas without intervening stroma. In this case,
recent studies show that discontinuous foci of prostate cancer
in needle-biopsies should be regarded and measured as one
continuous lesion [44, 45].
In short, tumor volume is an important parameter for
disease extent, but there is no consensus yet on the best
methodology for its assessment. It is clear that assignment
of the number of positive biopsies requires identification of
separate biopsy cores, even when they are fragmented due
to technical procedures. This can be performed by including
only one needle-biopsy per cassette, or marking multiple
individual cores in one cassette for instance by inking. It is
advised that no more than 3 biopsies should be included in
one cassette, provided that measures are taken to prevent
their curling and floating [46]. The extent of cancer in indi-
vidual cores is performed by actual measuring of the tumor’s
length with a ruler or by estimation of tumor percentage by
eye-balling. Measuring tumor length is objective and exact,
although more time-consuming. If estimation of percentage
is applied in daily practice, one should take into account
that detection of prostate cancer in short needle-biopsies
due to suboptimal technical procedures can result in over-
estimation of tumor percentage; for instance presence of
2mm prostate cancer in a 5mm biopsy results in a tumor
percentage of 40%, whichmight erroneously exclude patients
from active surveillance.
2.3. Perineural Invasion. The significance of perineural inva-
sion in prostate cancer biopsies remains questionable. In
a systematic review Harnden et al. addressed important
limitations of 21 studies on perineural invasion in biopsies
followed by radical prostatectomy or radiation therapy [47].
First, the presence of nerves in biopsies was not mandatory
for patient inclusion. Second, the number of biopsy cores
taken and the number of nerves present ranged widely.Third,
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Figure 1: (a) intraductal carcinoma of the prostate (100x magnification). (b) 34BE12 immunohistochemistry, demonstrating the presence
of basal cells supportive for intraductal carcinoma (100x magnification). (c) Cribriform growth pattern of Gleason grade 4 adenocarcinoma
(200x magnification).
pathologists were not obligated to routinely report on pres-
ence of perineural invasion; there were striking differences
in the frequency of perineural invasion when biopsies were
reviewed for study purpose. Interestingly, only 43% (18/42)
of surveyed urologists think that presence of perineural
invasion on prostate biopsy should influence treatment [48].
Ten out of 18 surveyed urologists (56%) indicated that it
helps planning nerve-sparing surgery. In contrast, nerve-
sparing surgerywas considered as a confounding factor in the
studies mentioned by Harnden et al. [47]. However, despite
limitations Harden et al. conclude that the weight of evidence
in studies ascribing prognostic significance to perineural
invasion appears to suggest that perineural invasion should
influence clinical decision-making [47]. For instance, Quinn
et al. demonstrated in a large cohort (𝑛 = 696) that per-
ineural invasion was a significant predictor for outcome in a
multivariable analysis [49]. Delancey et al. demonstrate that
perineural invasion on prostatic needle-biopsy is an indepen-
dent predictor for biochemical recurrence, disease-specific
survival, and overall survival after radical prostatectomy [50].
2.4. Intraductal Carcinoma: A High-Risk Lesion. Intraductal
carcinoma of the prostate is defined as a well-circumscribed
lesion surrounded by an intact basal cell layer distended
by overtly malignant-appearing epithelial populations [51]
(Figures 1(a) and 1(b)). Intraductal carcinoma forms a mor-
phologic continuum with high-grade prostate intraepithelial
neoplasia (PIN), which is the generally accepted precursor
of prostate cancer. While PIN is recognized by the presence
of cytologically malignant cells in preexistent prostate glands
of normal architecture, these glands should be enlarged in
intraductal carcinoma. In contrast to PIN, which can be an
isolated finding on prostate biopsy, intraductal carcinoma is
associated in 90% of cases with invasive carcinoma, mostly
of intermediate or high risk [52]. Up to date, three studies
on intraductal carcinoma all demonstrated its independent
predictive value for biochemical recurrence after radical
prostatectomy, treatment failure, and distant metastasis in
biopsies [53–55]. van der Kwast et al. showed that intra-
ductal carcinoma on needle-biopsies prior to external beam
radiotherapy with or without androgen deprivation therapy
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strongly predicted biochemical recurrence and early distant
metastasis in a cohort of 118 intermediate and 132 high risk
prostate cancer patients [55].
2.5. Percentage Gleason Grades 4 and 5. A proposed adaption
to the Gleason grading system by Vis et al. is the reporting
of percentage of Gleason grades 4/5 in prostatic needle-
biopsies [37]. In this study, containing 281 patients, amount
of high-grade cancer (length in mm, or percentage) in
the core biopsy was an independent prognostic factor for
biochemical recurrence and clinical relapse of prostate cancer
[37]. In addition, when biopsy Gleason score 7 cancers were
subcategorized into 3 + 4 and 4 + 3 cancers, the amount of
high-grade cancer was the strongest predictor of biochemical
recurrence free survival, whereas the Gleason grading system
was rejected in the presence of high-grade components [37].
So far, no other studies have yet validated the predictive value
of this parameter on prostatic needle-biopsies.
2.6. Gleason Grade 4 Patterns: Individual Prognostic Value.
Gleason grade 4 tumors represent a diverse group, containing
at least 4 distinctive growth patterns: fused, cribriform, ill-
defined, and glomeruloid [1, 14, 56]. Recently, Dong et al.
studied the prognostic value of these distinct Gleason grade
4 patterns and showed that cribriform growth, in particular,
was strongly associated with biochemical recurrence and dis-
tant metastasis after radical prostatectomy [57] (Figure 1(c)).
Only one publication has yet demonstrated the adverse prog-
nostic value of cribriform growth pattern in a biopsy series,
with radiotherapy as treatment, and biochemical recurrence
as clinical endpoint [54].
2.7. Extraprostatic Extension. Rarely, prostate cancer is infil-
trating extraprostatic fat tissue, seminal vesicle, or ejaculatory
ducts on needle-biopsies. Fat invasion by tumor on prostatic
needle-biopsy is considered as extraprostatic extension by
81% of surveyed pathologists from the European Network
of Uropathology [58]. If present, these features should
be mentioned in diagnostic needle-biopsies. Since signs
of extraprostatic extension are mostly seen in voluminous
prostate cancer with high Gleason score, these patients could
be less eligible for radical treatment.
2.8. Tumor-Associated Macrophages. Solid tumors grow in
a complex and dynamic stroma involving various cell
types, for example, leukocytes, fibroblasts, and endothelial
cells. Tumor-associated macrophages are part of the tumor
microenvironment and seem to influence solid tumor pro-
gression, for example, in colon, breast, and ovarian cancer
[59]. Nonomura et al. were the first to study its prognostic
relevance in prostate biopsies [60]. The presence of tumor-
associated macrophages, as immunohistochemically identi-
fied by the CD68 antibody in a cohort of 71 prostate cancer
patients treated with hormones, was associated with disease
recurrence after hormonal therapy. Furthermore, tumor-
associated macrophages count (>22 at 400x magnification),
PSA level, Gleason score ≥7, and extracapsular extension
were independent predictors for biochemical recurrence free
survival in multivariate analysis [60]. Studies on tumor-
infiltrating lymphocytes in prostatic needle-biopsies have not
yet been performed.
2.9. Summary
(i) To date, Gleason grading on prostatic biopsy is the
most important predictor for biochemical recurrence,
distant metastasis, and cancer-specific mortality in
prostate cancer.
(ii) Despite themodification in 2005 by the ISUP,Gleason
score upgrading at radical prostatectomy still ranges
between 26 and 50%.
(iii) Proposed predictors of upgrading are high preoper-
ative PSA, larger tumor percentage per biopsy core,
number of positive cores, and presence of perineural
invasion.
(iv) Proposed predictors of downgrading are smaller
tumor percentage per core and large prostate volume.
(v) Differing Gleason scores on prostate needle biopsies
could be a useful tool in decreasing the odds of
upgrading.
(vi) Tumor quantification is an important prognostic fac-
tor and implemented in clinical nomograms of pros-
tate cancer; there is, however, no consensus on the
best methodology for its assessment. Furthermore,
despite its fundamental role in clinical nomograms,
the effect on survival is relatively small.
(vii) Presence of perineural invasion on needle-biopsies is
an independent predictor for survival, and therefore
a recommended parameter to add in standardized
pathology reporting.
(viii) The amount of Gleason grade 4/5 in needle-biopsies
seems to have prognostic value; however, it needs to
be validated in large cohorts with strong endpoints.
(ix) Cribriform growth and/or intraductal spread are
promising histopathological markers in needle-bio-
psies.
(x) The prognostic value of tumor-associated inflam-
mation has recently been acknowledged in multiple
solid tumors and needs to be further investigated in
prostate cancer.
3. Molecular Markers
3.1. Ki-67. The Ki-67 protein is a cell proliferation marker,
which is expressed in G
1
, S, G
2
, and M phases of the cell
cycle being absent in resting (G
0
) cells. The Ki-67 labeling
index as determined by theMIB-1 antibody is the best studied
prostate cancer marker in needle-biopsies up to date [61–
66]. Ki-67 labeling index shows a strong correlation with
Gleason score on diagnostic biopsies [61, 63], on subsequent
radical prostatectomy [64–66], or both [62]. In a cohort of
91 patients, Rubio et al. found Ki-67 (cut-off value of 5%
positive nuclei) on needle-biopsies to be amarker for disease-
free survival after radical prostatectomy in univariate analysis
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[62]. Zellweger and colleagues found that Ki-67 labeling
index of ≥10% at biopsy cores in 279 patients independently
predicted seminal vesicle invasion and Gleason score on
subsequent radical prostatectomy [66]. In addition, they
found that Ki-67 was the only independent marker for
postoperative biochemical recurrence in a subgroup of low-
volume (<7%) or low-grade (Gleason score < 7) prostate
cancer at needle-biopsies. Tolonen et al. demonstrated that
Ki-67 in 247 primarily endocrine-treated prostate cancer
patients was associated with progression-free survival [63].
Ki-67 labeling ≥ 10% on 293 microarrayed needle-biopsies
had independent predictive value for disease-specific death
together withGleason score and PSA [61]. Recently, Tollefson
et al. calculated in a cohort of 451 prostate cancer needle-
biopsies that every 1% increase in Ki-67 expression resulted
in a 12% increased risk of cancer-specific death after radical
prostatectomy [29].Whereas these studies all show additional
value of Ki-67 expression in needle-biopsies with aggressive
disease features, two studies focused on the relation of Ki-67
labeling in needle-biopsies and presence of indolent disease
on radical prostatectomy. In a well-defined screening cohort
Vis et al. were not able to find a significant association of Ki-
67 ≥ 10% with significant prostate cancer at radical prostate-
ctomy in 81 patients [64]. Wolters et al. were also not able to
find a significant association of high Ki-67 expression (>3%)
with significant prostate cancer at radical prostatectomy in
86 patients [65]. Taken together, enhanced Ki-67 labeling
at needle-biopsy is associated with adverse clinicopathologic
features and disease-specific death in general prostate cancer
populations.
3.2. p27. p27kip1 is a cyclin-dependent kinase (cdk) inhibitor.
It inhibits cell cycle progression in G
1
phase by preventing
activation of cyclin E-cdk2 and cyclin D/-cdk4 complexes
[67]. Loss of p27 has been widely associated with progression
of different tumor types, including breast, colorectal, and
lung cancer [67]. Generally, p27 expression in prostate cancer
needle-biopsies correlateswell with the p27 labeling in radical
prostatectomy samples [64, 67]. In prostate cancer, various
groups have shown that loss of p27 expression was associated
with more aggressive disease parameters. Thomas et al.
demonstrated that low expression (<30%) of p27 in needle-
biopsies correlated with higher Gleason score and pT-stage
at radical prostatectomy [67]. In this relatively small cohort
of 44 patients, tumors with low p27 expression showed a
trend towards shortened biochemical recurrence free survival
after operation. Vis et al. showed that p27 expression in
<50% together with Gleason score were the only significant
parameters to predict clinically significant disease at radical
prostatectomy in a screen-detected cohort of 81 prostate
cancer patients [64]. In addition, we found that p27 in <90%
in a low-risk prostate cancer cohort was an independent
parameter of clinically significant prostate cancer in 86
radical prostatectomy samples [65]. Therefore, loss of p27 is
a marker of more aggressive prostate cancer, although the
number of patients is limited and different standard cutoff
levels have been used by various groups.
3.3. EZH2. Enhancer of zeste homologue 2 (EZH2) belongs
to the Polycomb-group proteins and is important in main-
taining cell identity and regulation of the cell cycle [68,
69]. EZH2 has been reported to be of both prognostic and
therapeutic value in different tumors, such as small cell lung
carcinoma [70], breast cancer [71, 72], cervical carcinomas
[73], urinary tract carcinoma [74], and lymphoma [75].
Through gene expression profiling, EZH2 was found to
be overexpressed in hormone-refractory metastatic prostate
cancer [69]. Overexpression of EZH2 in radical prostatec-
tomy samples was associated with poor prognosis [69, 76–
78]. In a set of 86 needle-biopsies of screen-detected low-
risk prostate cancer, EZH2 expression >1% was associated
with clinically significant tumors on radical prostatectomy,
defined as presence of extraprostatic extension, Gleason
grade 4/5 or tumor volume ≥0.5mL [65]. In the same
study, no prognostic value was found for Polycomb-group
protein BMI1. Tolonen et al. found independent predictive
value for EZH2 (expression level of >15%) for progression-
free survival in 247 hormone-treated biopsies [63]. While
enhanced EZH2 expression in prostate cancer biopsies has
independent prognostic value, there is no consensus yet on
cutoff points in clinical practice.
3.4. TMPRSS2:ERG. Fusion of the androgen-dependent
TMPRSS2 gene to ETS-transcription factor ERG (TMPRSS2
:ERG) is one of the most common genetic alterations in pros-
tate cancer occurring in 50%–70% of tumors [79]. Many
groups have analyzed the presence of TMPRSS2:ERG fusion
or ERG protein expression in prostate cancer cohorts with
variable outcome [80–92]. Barros-Silva et al. used fluores-
cent in situ hybridization (FISH) to detect TMPRSS2-ERG
rearrangement in a cohort of 200 biopsies and found an
association with low PSA levels at diagnosis and low Gleason
score [93]. In needle-biopsies immunohistochemical ERG
detection can be used to discriminate prostate cancer from
its mimickers, although the additional value to other markers
such as p63, basal cell keratin 5, and AMACR is limited
[92, 94–99]. In an active surveillance cohort of 265 men,
Berg et al. found a strong correlation between ERG protein
expression and disease-progression [100]. Likewise, Hagglof
et al. showed a shorter survival of prostate cancer patients
on watchful waiting when ERG was expressed [101]. They
found a cumulative 2-year progression rate of 59% in the
ERG-positive group versus 22% in the ERG-negative group.
Finally, expression of ERG in high-grade PIN was associ-
ated with a higher chance of developing prostate cancer at
subsequent biopsies [102]. ERG immunohistochemistry is an
easy to perform methodology for detecting TMPRSS2:ERG
fusion in prostate cancer. While the clinical relevance of
TMPRSS2:ERG fusion on radical prostatectomy specimens
is unresolved yet, most reports indicate that ERG expression
on biopsy, in surveillance cohorts can select a subgroup with
higher chance to progression.
3.5. Neuroendocrine Differentiation. In many prostate can-
cers, scattered tumor cells show neuroendocrine differen-
tiation as demonstrated by antibodies to Chromogranine,
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Synaptophysine, or Serotonine. After hormonal therapy, the
relative number of neuroendocrine cells is increased, puta-
tively due to their androgen-independent nature [103–105].
Despite extensive studies on neuroendocrine differentiation
in relation to castration-resistance, this feature is rarely
studied in pretreatment biopsies. Krauss and colleagues have
shown that Chromogranine An expression of >1% in prostate
cancer biopsies is an independent predictor for distant
metastasis and cause-specific survival after primary radiation
therapy [106, 107].
3.6. c-MYC. The oncogene c-MYC located at 8q24 encodes
a transcription factor involved in cell cycle progression,
cell growth, proliferation, protein synthesis, mitochondrial
function, stem cell renewal, and DNA replication [108, 109].
c-MYC is amplified in approximately 70% of clinical prostate
cancer [93, 110, 111]. Ribeiro et al. found that patients with
gain of MYC gene copy numbers in a group of 60 prostate
cancer needle-biopsies using FISH were significantly at risk
for disease-specific death [110]. Bastacky et al. showed that
amplification of c-MYC in needle-biopsies with high-grade
PIN was predictive of finding prostate cancer in subsequent
biopsies [112]. The potential predictive value of c-MYC was
confirmed by Zafarana et al. in a cohort of 126 needle
biopsies, where they found c-MYC gain alone to be prognostic
for tumor recurrence after radiotherapy [111]. c-MYC gain
combined with loss of PTEN further increased the predictive
value for recurrence after radiotherapy.
3.7. PTEN. Phosphatase and tensin homologue (PTEN) is a
tumor suppressor gene which is inactivated in many different
tumors, including prostate cancer [113]. On large cohorts of
radical prostatectomy samples and transurethral resection
(TUR) samples, PTEN loss has been associated with bone
metastases, resistance to radiotherapy and chemotherapy,
progression to androgen-independent disease, and disease
recurrence after surgery [113, 114]. Zafarana et al. found that
PTEN loss alone and in combination with c-MYC gain were
independently associated with biochemical recurrence after
radiation therapy in a group of 126 intermediate-risk prostate
cancer biopsies [111].
3.8. APC. Using quantitative methylation-specific PCR
(QMSP) Henrique and colleagues showed that hypermethyl-
ation of APC, GSTP1, and RASSF1A in 83 prostate cancers
at sextant needle-biopsies was associated with poor disease-
specific survival [115]. Besides clinical stage, hypermethyl-
ation of APC was independently predictive for decreased
disease-free and disease-specific survival. Methylation of
CCND2 andRARB2 in the same study did not have predictive
value for disease outcome.
3.9. Molecular Signatures. Subgroups with uniquemolecular,
pathologic, clinical, and therapy-sensitivity, as have been
defined in breast cancer, have not been delineated in prostate
cancer yet. Nevertheless, recently gene signatures have been
put forth to predict prostate cancer behavior. Klein et al.
demonstrated that a 17-gene assaywas able to identify patients
with high-grade and high-stage disease at radical prostate-
ctomy in a cohort of 395 men with low- to intermediate-
risk prostate cancer at biopsies [116]. In addition, Irshad
et al. identified a 3-gene signature of FGFR1, PMP22, and
CDKN1A, which could accurately predict the outcome of low
Gleason score prostate cancer in different cohorts [117]. For
clinical implementation and validation this group applied
immunohistochemistry for the respective proteins. In a lim-
itedmatched cohort of 43 low-risk prostate cancer patients on
active surveillance theywere perfectly able to identify patients
with failure upon active surveillance by reduced expression
of these 3 proteins. Gene-based signatures therefore are a
promising tool for risk stratification and might gain wider
application if translation to easy-to-use procedures such as
immunohistochemistry is available.
3.10. BiopsyMarkers without Prognostic Value. While numer-
ous markers have been shown to correlate with adverse
clinicopathologic parameters on radical prostatectomy, just
a limited number of these has been investigated in pre-
treatment needle-biopsies. Briefly, we also want to mention
markers that have been investigated on biopsies but did not
show additional value. In a group of 91 prostate cancer needle-
biopsies, Bax, Bcl-2, and Cox-2 did not show independent
predictive value for disease-free survival, althoughCox-2 was
predictive in univariate analysis [62]. On a large cohort of
247 patients with primary endocrine treatment, Tolonen et
al. demonstrated thatminichromosomemaintenance protein
7 (MCM7) was a significant albeit not independent marker
for disease-progression [63]. We validated the prognostic
value of Cystein-rich secretory protein 3 (CRISP-3) and
𝛽-Microseminoprotein (𝛽-MSP) in a screening cohort of
174 men. We found that expression of these markers was
correlated with Gleason score, tumor volume, and pT-stage
and significant disease on subsequent radical prostatectomy
samples but were not able to predict recurrence [118].
3.11. Summary
(i) The cell proliferationmarker Ki-67 (MIB-1) is the best
studied immunohistochemical marker in prostate
with independent prognostic value in multiple stud-
ies.
(ii) Cyclin-dependent kinase inhibitor p27 and Poly-
comb-group protein EZH2 are both promising
immunohistochemical markers for predicting dis-
ease outcome.
(iii) The clinical significance of TMPRSS:ERG fusion or
ERG protein overexpression is still controversial,
although some studies demonstrate adverse prog-
nostic value in active surveillance/watchful waiting
cohorts.
(iv) Amplification of c-MYC, PTEN loss, and APC hyper-
methylation are promising markers for predicting
disease-specific death, albeit only demonstrated in a
small number of biopsy cohorts.
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(v) Identification of complex gene signatures offers novel
promising platforms for predicting disease-outcome.
Routine implementation in local pathology laborato-
ries is currently not applicable.
4. Conclusions
Investigation of potential novel predictivemarkers in prostate
cancer needle-biopsies is of importance to affect clinical
decision-making and to be implemented in daily practice. A
prerequisite in analyzing novel markers on needle-biopsies
is the presence of well-characterized patient cohorts with
clinical follow-up and availability of prostate cancer tissue for
actual testing. Secondary and tertiary cancer centers often do
not have original tissue blocks for further research on site. In
addition, small foci of prostate cancer are often not present
anymore in the remaining paraffin block. Incorporation of
both detailed histopathological prostate cancer features and
molecularmarkers can support optimal therapeutic decision-
making in individual patients.
Comprehensive reporting of novel histopathological
parameters such as percentage Gleason grade 4/5, intraductal
carcinoma and potentially Gleason grade 4 growth pattern
is a fast and cheap way to better estimate a prostate cancer’s
future clinical behavior in daily practice. Various molecular
markers such as Ki-67, p27, EZH2, and ERG immunohisto-
chemistry, as well as c-MYC and PTEN in situ hybridization,
can putatively sustain and improve pathologic diagnosis. The
variability in patient cohorts, clinical endpoints, technical
methodology, and quantification, however, require prospec-
tive studies in well-characterized patient groups before
implementation in daily practice is feasible. Identification of
complex gene-signatures is a recent and promising tool in
stratification of prostate cancer patients, though still costly
and not easily applicable in daily practice.
Last decade, the diagnosis of prostate cancer has changed
significantly. Pathologic Gleason scoring has been modified;
sextant biopsies have widely been replaced by 10 to 12 or
more biopsy sampling protocols; image-guided biopsies sup-
plement established biopsy schemes and facilitate sampling
of biologically relevant tumor areas. It is difficult to interpret
the additional value of established prognostic factors of
earlier studies in contemporary prostate cancer health care.
We advocate that incorporation of novel histopathological
parameters such as percentage Gleason grade 4/5, presence of
intraductal carcinoma, and Gleason grade 4 growth patterns
in daily pathology practice as well as prostate cancer studies
offer an inexpensive and short-term opportunity to improve
prostate cancer health care and interpret the additional value
of promising molecular markers.
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